Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy?

× No keyword cloud information.

3 in total

1. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT.

Authors: Sandip Basu; Bhawna Sirohi; Shailesh V Shrikhande
Journal: Eur J Nucl Med Mol Imaging Date: 2014-05-27 Impact factor: 9.236

2. The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Authors: Sandip Basu; Vikas Ostwal
Journal: Eur J Nucl Med Mol Imaging Date: 2016-08-20 Impact factor: 9.236

Review 3. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Authors: Sandip Basu; Sudipta Chakraborty; Rahul V Parghane; Rohit Ranade; Pradeep Thapa; Ramesh V Asopa; Geeta Sonawane; Swapna Nabar; Hemant Shimpi; Ashok Chandak; K V Vimalnath; Vikas Ostwal; Anant Ramaswamy; Manish Bhandare; Vikram Chaudhari; Shailesh V Shrikhande; Bhawna Sirohi; Ashutosh Dash; Sharmila Banerjee
Journal: Am J Nucl Med Mol Imaging Date: 2020-08-25

3 in total

Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy?

1. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT.

2. The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Review 3. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Review 3. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.